Moleculin Biotech

+$0.07 (+4.86%) Today

+$0.02 (+1.32%) As of 12:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MBRX and other ETFs, options, and stocks.

About MBRX

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which engages in the development of treatments for highly resistant cancers and viruses. Its clinical stage drugs include Annamycin, an Anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia (AML), and WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer, and AML.

CEO

Walter V. Klemp

Employees

Headquarters

Houston, Texas

Founded

2015

MBRX Key Statistics

Market cap

Price-Earnings ratio

—

Dividend yield

—

Average volume

57.48K

High today

$1.54

Low today

$1.41

Open price

$1.44

Volume

67.22K

52 Week high

$3.99

52 Week low

$1.02

MBRX News

BenzingaMay 26

Moleculin Biotech Doses Healthy Volunteers For Covid-19 In Early-Stage Study Of WP1122

Moleculin Biotech, Inc. MBRX announced dosing of subjects in its Phase 1a clinical study of WP1122 in healthy volunteers for the treatment of COVID-19. The fir

MBRX Earnings

-$0.36

-$0.24

-$0.12

$0.00

Q3 FY20

Q4 FY20

Q1 FY21

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

Estimated

— per share

Actual

Expected Aug 10, After Hours